Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fractional Shares

1,709.56
-2.4785-0.14%
Number of Gainers:690
Number of Losers:321
Number of Flat:17
PE:- -
High:1,718.87
Open:1,711.39
Low:1,686.18
Close:1,712.04
Volume:5.94B
Turnover:696.05B
Market Cap:82.56T
Float Cap:77.15T

Loading ...

Liaoning Province Launches "QR Code Entry" Pilot Program for Administrative Inspections of Enterprises

Deep News
·
Oct 13

"Zhuge Space" Construction Gets Its "Blueprint"

Deep News
·
Oct 13

Gateway Mining Unveils Promising IP Survey Results at Yandal Project

TIPRANKS
·
Oct 13

Positive Report for Netwealth Group Ltd. (NWL) from Citi

TIPRANKS
·
Oct 13

AMP (AMLTF) Gets a Buy from Citi

TIPRANKS
·
Oct 13

Qube's New Bull Thinks Earnings Growth Underappreciated -- Market Talk

Dow Jones
·
Oct 13

Immutep receives FDA agreement on optimal dose for efti and advances Phase III lung cancer trial in US

Reuters
·
Oct 13

Press Release: IsoEnergy to Acquire Toro Energy, Strengthening a Top-Tier Uranium Portfolio in a Rising Market

Dow Jones
·
Oct 13

Austco Healthcare Unveils FY 2025 Growth Strategy

TIPRANKS
·
Oct 13

Peninsula Energy Secures A$69.9 Million Funding to Boost Uranium Production

TIPRANKS
·
Oct 13

Infini Resources Expands Portland Creek Uranium Project by 68%

TIPRANKS
·
Oct 13

Albion Resources Unveils Promising Gold Corridor at Yandal West

TIPRANKS
·
Oct 13

U.S. stock futures surge as Trump dismisses latest China tariff tensions: 'It will all be fine'

Dow Jones
·
Oct 13

Finder Energy Fast-Tracks Timor-Leste Oil Field Development

TIPRANKS
·
Oct 13

Blue Star Helium Advances Galactica Project with Key Lease Agreement

TIPRANKS
·
Oct 13

Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Reuters
·
Oct 13

Moderna announces promising early clinical data for mRNA4359 cancer antigen therapy at ESMO 2025

Reuters
·
Oct 13

BRIEF-Moderna Says It Presents Promising Early Data For Investigational Cancer Antigen Therapy

Reuters
·
Oct 13

Moderna: Presents Promising Early Data for Investigational Cancer Antigen Therapy

THOMSON REUTERS
·
Oct 13

Moderna: Mrna-4359 in Combination With Pembrolizumab Showed Consistently Manageable Safety Profile, No New Immune-Related Adverse Events

THOMSON REUTERS
·
Oct 13